Overview
AOD 9604 is a specialized peptide derivative modeled after the C-terminal end of the human growth hormone molecule. Unlike full-sequence HGH, this hexadecapeptide focuses almost exclusively on lipid metabolism, making it a highly targeted tool for weight management. By mimicking the natural hormone's ability to stimulate fat burning while blocking the creation of new fat stores, it offers a metabolic advantage for those struggling with obesity or looking to refine their body composition during a cutting cycle.
Beyond its primary role in weight loss, clinical research indicates that AOD 9604 may contribute significantly to musculoskeletal integrity. It has shown promise in supporting the repair of bone and cartilage, potentially offering relief for those suffering from osteoarthritis or general joint discomfort. Because it does not trigger the typical growth-hormone-related increase in insulin resistance, it is often viewed as a safer profile for long-term metabolic health compared to full-sequence growth hormone therapy.
Mechanism of action
AOD 9604 is a synthetic analog of the C-terminal fragment of human growth hormone (hGH 177-191) that specifically regulates fat metabolism by stimulating lipolysis and inhibiting lipogenesis without impacting insulin sensitivity or IGF-1 levels.
Reported benefits
- ▸Accelerates the breakdown of stored body fat (lipolysis)
- ▸Prevents the formation of new fatty acids (lipogenesis)
- ▸Supports joint health and cartilage repair without affecting blood sugar
- ▸Enhances metabolic rate during cutting phases in fitness regimes
Reported side effects
- ·Minimal side effects reported in clinical trials
Often stacked with
Not specified